Clinical trials: B Cell
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)
Safety and Efficacy Evaluation of CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT03229876
- Testing
- CD19-UCART
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Chronic Lymphocytic Leukemia
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the…
- Trial name
- NCT01081015
- Where
- 165 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- Celgene
Systemic Lupus Erythematosus (SLE)
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE have ongoing disease activity despite treatment with standard of care…
- Trial name
- NCT04058028
- Testing
- Rozibafusp Alfa
- Where
- 147 sites in United States, Argentina and 17 more
- Volunteers
- 244 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV…
- Trial name
- SIGMA (NCT07582432)
- Testing
- Gamunex-C, 10% Injectable Solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Grifols Biologicals, LLC
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of…
- Conditions
- Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory, Follicular Lymphoma ( FL), Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Trial name
- CD20/19 CAR T (NCT06703892)
- Testing
- GF-CART01
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- GenomeFrontier Therapeutics TW Co., Ltd.
B-precursor Acute Lymphoblastic Leukemia, ALL
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.
- Conditions
- B-precursor Acute Lymphoblastic Leukemia, ALL, GNR-084
- Trial name
- NCT04601584
- Testing
- Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084
- Where
- 3 sites in Russia
- Volunteers
- 14 people
- Sponsor
- AO GENERIUM
B-ALL, Leukemia
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.
- Trial name
- NCT07556757
- Testing
- CD19 t-haNK
- Where
- 2 sites in South Africa
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Leukemia
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00086775
- Testing
- alemtuzumab, rituximab, fludarabine phosphate
- Where
- 5 sites in United States
- Sponsor
- Bayer
Double Cord Blood Transplant, Acute Myelogenous Leukemia
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant.
- Conditions
- Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- USBTXA127CBT (NCT01300611)
- Testing
- TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tarix Pharmaceuticals
Relapsed/Refractory Chronic Lymphocytic Leukemia
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with…
- Trial name
- NCT05944978
- Testing
- GNC-035
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
- Trial name
- NCT05885555
- Testing
- Ianalumab
- Where
- 24 sites in United States, Argentina and 11 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic…
- Trial name
- NCT01905943
- Testing
- Bendamustine, Chlorambucil, Cyclophosphamide
- Where
- 174 sites in Argentina, Belgium and 29 more
- Volunteers
- 979 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia, Phase Ib). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated…
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT04018248
- Testing
- BR101801 (Phase Ia), BR101801 (Phase Ib)
- Where
- 9 sites in United States, South Korea
- Volunteers
- 26 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Multiple Myeloma, Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with…
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
- Trial name
- NCT04045028
- Testing
- Tiragolumab, Daratumumab/rHuPH20, Rituximab
- Where
- 14 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
- Trial name
- PCYC-1109-CA (NCT01217749)
- Testing
- PCI-32765, ofatumumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Non-Hodgkin
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of…
- Trial name
- CHRONOS-4 (NCT02626455)
- Testing
- Copanlisib (BAY80-6946), Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Australia and 33 more
- Volunteers
- 551 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.